1.
Huang K- lin, Mashl J, Wu Y, et al. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell. 2018;173(2):355-370.e14. doi:10.1016/j.cell.2018.03.039.
1.
Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500-4. doi:10.1038/nature11183.
1.
Konieczkowski DJ, Johannessen CM, Abudayyeh O, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discov. 2014;4(7):816-27. doi:10.1158/2159-8290.CD-13-0424.
1.
Qin Y, McAllister SS. SPSB1 may have MET its match during breast cancer recurrence. Cancer Discov. 2014;4(7):760-1. doi:10.1158/2159-8290.CD-14-0505.